Title:
BLAUTIA SP. BACTERIUM-DERIVED NANOVESICLES AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/164283
Kind Code:
A1
Abstract:
The present invention relates to Blautia sp. bacterium-derived vesicles and a use thereof. The present inventors experimentally found that significantly reduced levels of the vesicles are in clinical samples from patients with colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, myocardial infarction, atrial fibrillation, and variant angina, compared to normal persons and that administration of vesicles isolated from the strain remarkably repressed the inflammatory mediator secretion induced by pathogenic vesicles such as vesicles derived from E. coli. The Blautia sp. bacterium-derived vesicles according to the present invention can be effectively used to develop a method for diagnosis of colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, myocardial infarction, atrial fibrillation, or variant angina and a composition for prevention, alleviation, or treatment of colorectal disease, liver disease, pancreatic disease, cholangiocarcinoma, ovarian cancer, bladder cancer, myocardial infarction, atrial fibrillation, variant angina, or graft-versus-host disease.
Inventors:
KIM YOON-KEUN (KR)
Application Number:
PCT/KR2019/002102
Publication Date:
August 29, 2019
Filing Date:
February 21, 2019
Export Citation:
Assignee:
MD HEALTHCARE INC (KR)
International Classes:
C12Q1/689; A23L33/135; A61K35/74; A61P35/00; A61P37/00; C12Q1/6851
Domestic Patent References:
| WO2012159023A2 | 2012-11-22 |
Foreign References:
| KR20180006303A | 2018-01-17 | |||
| KR20180012846A | 2018-02-06 | |||
| KR20160073157A | 2016-06-24 | |||
| US20120058094A1 | 2012-03-08 |
Attorney, Agent or Firm:
LEE, Myoung-Jin (KR)
Download PDF: